Back to search
Advanced Solid Tumors With HER2 Abnormalities
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Advanced Solid Tumors With HER2 Abnormalities trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Advanced Solid Tumors With HER2 Abnormalities trials you may qualify forPhase 1/2, open-label study of ETX-636 in participants with advanced solid tumors
Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor…
IDE574 is a synthetically manufactured small molecule inhibitor that co-targets the lysine acetyltransferase enzymes KAT6 and KAT7. The purpose of this study i…
This is a phase 1b, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics of Sapu003 in combination with Exemestane in in pat…
This study is designed to investigate the safety and tolerability of a new drug, AZD5363, in patients with advanced cancer - and to identify a dose and schedule…
This is a First-in-Human (FIH), 2-part, Phase 1/2, open-label, multicenter study design to evaluate the safety, tolerability, PK, pharmacodynamics, PGx, and eff…
The BCCA Oncopanel is a clinical assay being developed to determine genotype status of a prospectively defined set of genes. The purpose of this pilot study is…